| Scrip Code | 539872 |
|---|---|
| NSE Symbol | BAJAJHCARE |
| MSEI Symbol | NOTLISTED |
| ISIN | INE411U01027 |
| Name of company | BAJAJ HEALTHCARE LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 08-05-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 02-05-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Fourth quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Audited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Audited |
| Segment Reporting | Single segment |
| Description of single segment | Pharmaceuticals |
| Start date and time of board meeting | 08-05-2026 17:15:00 |
| End date and time of board meeting | 08-05-2026 18:30:00 |
| Whether cash flow statement is applicable on company | Yes |
| Type of cash flow statement | Cash Flow Indirect |
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Whether the company has any related party? | Yes |
| Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? | Yes |
| (I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public | NA |
| (II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. | NA |
| Whether the company is a high value debt listed entity according to regulation 15 (1A)? | No |
| (a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication? | |
| (b) If answer to above question is No, please explain the reason for not complying. | |
| Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? | Yes |
| Latest Date on which RPT policy is updated | 11-02-2025 |
| Indicate Company website link for updated RPT policy of the Company | https://www.bajajhealth.com/policies/ |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | Yes |
| No. of times funds raised during the quarter | 1 |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No |
| During the period ended 31.03.2026, there is no default on Loans and Debt Securities. | |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 15,305.75 | 61,103.14 | |
| Other income | 295.62 | 713.39 | |
| Total income | 15,601.37 | 61,816.53 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 9,210.06 | 30,619.95 |
| (b) | Purchases of stock-in-trade | 0.00 | 0.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (1,059.01) | 1,019.54 |
| (d) | Employee benefit expense | 1,630.11 | 6,275.26 |
| (e) | Finance costs | 556.58 | 2,223.37 |
| (f) | Depreciation, depletion and amortisation expense | 762.87 | 2,754.84 |
| (f) | Other Expenses | ||
| 1 | Brokerage & Commission | 92.33 | 444.33 |
| 2 | Consumption of Stores Spares and Maintainence | 255.68 | 1,704.76 |
| 3 | Freight Forwarding & Transport | 382.76 | 1,444.02 |
| 4 | Insurance Expenses | 59.70 | 301.25 |
| 5 | Legal & Professional Expenses | 219.44 | 828.61 |
| 6 | Material Testing & Inspection Charges | 37.86 | 268.93 |
| 7 | Miscellaneous Expenses | 173.47 | 400.30 |
| 8 | Power and Fuel | 1,031.11 | 3,001.99 |
| 9 | Processing & Labour Charges | 574.72 | 2,013.71 |
| 10 | Others | 429.91 | 2,298.71 |
| Total other expenses | 3,256.98 | 12,706.61 | |
| Total expenses | 14,357.59 | 55,599.57 | |
| 3 | Total profit before exceptional items and tax | 1,243.78 | 6,216.96 |
| 4 | Exceptional items | (3,324.66) | (3,324.66) |
| 5 | Total profit before tax | (2,080.88) | 2,892.30 |
| 6 | Tax expense | ||
| 7 | Current tax | 0.00 | 0.00 |
| 8 | Deferred tax | (139.60) | 761.26 |
| 9 | Total tax expenses | (139.60) | 761.26 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | (1,941.28) | 2,131.04 |
| 12 | Profit (loss) from discontinued operations before tax | (230.18) | (511.69) |
| 13 | Tax expense of discontinued operations | 113.60 | 42.74 |
| 14 | Net profit (loss) from discontinued operation after tax | (343.78) | (554.43) |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | (2,285.06) | 1,576.61 |
| 17 | Other comprehensive income net of taxes | 4.86 | 60.98 |
| 18 | Total Comprehensive Income for the period | (2,280.20) | 1,637.59 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 1,683.13 | 1,683.13 | |
| Face value of equity share capital | 5 | 5 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | 1,683.13 | |
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | -6.08 | 6.73 | |
| Diluted earnings (loss) per share from continuing operations | -6.07 | 6.72 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | -1.08 | -1.75 | |
| Diluted earnings (loss) per share from discontinued operations | -1.08 | -1.75 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | -7.16 | 4.98 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | -7.15 | 4.97 | |
| 24 | Debt equity ratio | 44.00 | 44.00 |
| 25 | Debt service coverage ratio | 124.00 | 215.00 |
| 26 | Interest service coverage ratio | 323.00 | 380.0 |
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | 1. The above Financial Results of Bajaj Healthcare Limited the Company have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 08 May 2026. These results have been subjected to limited review by the Statutory auditors who have expressed an unmodified review conclusion. 2. The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year. 3. The Company deals in pharmaceuticals products formulations and active pharmaceutical ingredients components which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals. 4. In the year ended 31 March 2024, the Board of Directors had approved to sale disposal of undertaking unit s on going concern basis, situated at plot no N92, L9 3 T 30, MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D 2 CH 42 D 2 CH 43 Dahej industrial area, GIDC, Bharuch, Gujarat which were acquired under SARFAESI ACT, 2022 from Saraswat Bank and plot no. E 62 and E 63 MIDC Tarapur Taluka Boisar, District Palghar, Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale disposal under Ind AS 105 Non current Assets Held for Sale and Discontinued Operations. The results of the operation of these units have been presented separately on the Statement of Profit and Loss as Discontinued Operations. Out of these, one unit situated at plot no. N 92 was sold during the Quarter ended 31 March 2024 and one unit situated at plot no. L 9 3 was sold during the Quarter ended 31 March 2026. The total value of assets classified as held for sale represents lower of carrying value or fair value. 5. The Board of Directors at its meeting held on 18 March 2026, considered and approved the allotment of 20,79,409 fully Paid up Equity Shares of the Company of face value of Rs. 5 each the Equity Shares to the Promoter, Promoter Group and Person s belonging to the Non Promoter Public Category, pursuant to the exercise of the option for Conversion of Warrants into Equity Shares at a price of Rs. 338 per Equity Share including a premium of Rs. 333 for each Convertible Warrant. The allotment has been made pursuant to the Special Resolution passed by the shareholders at the Extra Ordinary General Meeting held on 7 August 2024, in accordance with the provisions of the SEBI Issue of Capital and Disclosure Requirements Regulations, 2018. Earlier, on 19 September 2024, the Company had allotted 39,84,852 equity shares and 20,79,409 convertible warrants, raising an aggregate amount of Rs. 15225.90 lakhs. This amount included 25 percentage of the warrant issue price, aggregating to Rs.1,757.10 lakhs, which was received at the time of allotment of the convertible warrants. The balance 75 percentage i.e. Rs 5,271.30 lakhs of the issue price has now been received upon the allotment of 20,79,409 equity shares pursuant to the exercise of conversion rights attached to the warrants. The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities. 6. The Company had entered into a Transfer of Technical Know how arrangement with a customer for one of the products manufactured by the Company. The Technical know how was ultimately to be used by a customer in Middle East. Due to ongoing regional instability in Middle East, the customer was not able to meet its committed timeline. Hence, the Company has reversed the income recognised in earlier year amounting to Rs. 3,324.66 lakhs, in the quarter ended 31 March 2026. 7. In April 2025, the Company acquired Genrx Pharmaceuticals Private Limited in Liquidation Genrx, on a going concern basis. Genrx is an existing company incorporated under the provisions of the Companies Act, 1956. The acquisition was made for a total consideration of Rs. 1,085 lakhs. Subsequently, on 3 June 2025, the Company filed an application with the Honble National Company Law Tribunal NCLT, Mumbai, seeking certain reliefs and concessions necessary for the effective implementation of the acquisition and takeover of Genrx as a going concern, which is pending with NCLT as on 31 March 2026. Hence, Genrx has not been considered a subsidiary for consolidation purpose, pending requisite approvals from the NCLT, as control, defined under Ind AS 110 Consolidated Financial Statements is notB established. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | Debt Equity Ratio is 1.24 for FY 2026 and 2.15 for FY 2025 |
| Interest service coverage ratio | ISCR is 3.23 for FY 2026 and 3.80 for FY 2025 |
| Particulars | Year ended (dd-mm-yyyy) | |
|---|---|---|
| Date of start of reporting period | 01-04-2025 | |
| Date of end of reporting period | 31-03-2026 | |
| Whether results are audited or unaudited | Audited | |
| Nature of report standalone or consolidated | Standalone | |
| Assets | ||
| 1 | Non-current assets | |
| Property, plant and equipment | 24,722.48 | |
| Capital work-in-progress | 794.14 | |
| Investment property | 0.00 | |
| Goodwill | 0.00 | |
| Other intangible assets | 98.18 | |
| Intangible assets under development | 0.00 | |
| Biological assets other than bearer plants | 0.00 | |
| Investments accounted for using equity method | 0.00 | |
| Non-current financial assets | ||
| Non-current investments | 0.33 | |
| Trade receivables, non-current | 0.00 | |
| Loans, non-current | 0.00 | |
| Other non-current financial assets | ||
| 1 | Fixed deposits with remaining maturity beyond 12 months | 284.62 |
| 2 | Amount paid for Investment in Genrx Pharma | 1,085.00 |
| Total of other non-current financial assets | 1,369.62 | |
| Total non-current financial assets | 1,369.95 | |
| Deferred tax assets (net) | 1,065.01 | |
| Other non-current assets | ||
| 1 | Income Tax Receivables | 370.74 |
| Total of other non-current assets | 370.74 | |
| Total non-current assets | 28,420.50 | |
| 2 | Current assets | |
| Inventories | 21,600.96 | |
| Current financial asset | ||
| Current investments | 0.00 | |
| Trade receivables, current | 23,385.38 | |
| Cash and cash equivalents | 3,723.54 | |
| Bank balance other than cash and cash equivalents | 75.19 | |
| Loans, current | 0.00 | |
| Other current financial assets | ||
| Total of other current financial assets | 522.67 | |
| Total current financial assets | 27,706.78 | |
| Current tax assets (net) | 0.00 | |
| Other current assets | ||
| 1 | Balance with Statutory Authority | 3,244.20 |
| 2 | Deposit With Public Authorities and Others (Refer 10.1) | 765.60 |
| 3 | Prepaid assets | 955.95 |
| 4 | Capital advances | 2,250.00 |
| 5 | Advance to Suppliers | 384.73 |
| Total of other current assets | 7,600.48 | |
| Total current assets | 56,908.22 | |
| 3 | Non-current assets classified as held for sale | 6,993.00 |
| 4 | Regulatory deferral account debit balances and related deferred tax Assets | 0.00 |
| Total assets | 92,321.72 | |
| Equity and liabilities | ||
| 1 | Equity | |
| Equity attributable to owners of parent | ||
| Equity share capital | 1,683.13 | |
| Other equity | 51,617.10 | |
| Total equity attributable to owners of parent | 53,300.23 | |
| Non controlling interest | ||
| Total equity | 53,300.23 | |
| 2 | Liabilities | |
| Non-current liabilities | ||
| Non-current financial liabilities | ||
| Borrowings, non-current | 4,756.57 | |
| Trade payables, non-current | ||
| (A) Total outstanding dues of micro enterprises and small enterprises | 0.00 | |
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 0.00 | |
| Total Trade payable | 0.00 | |
| Other non-current financial liabilities | ||
| 1 | Lease Liabilities | 298.83 |
| Total of other non-current financial liabilities | 298.83 | |
| Total non-current financial liabilities | 5,055.40 | |
| Provisions, non-current | 717.85 | |
| Deferred tax liabilities (net) | 0.00 | |
| Deferred government grants, Non-current | 0.00 | |
| Other non-current liabilities | ||
| Total of other non-current liabilities | ||
| Total non-current liabilities | 5,773.25 | |
| Current liabilities | ||
| Current financial liabilities | ||
| Borrowings, current | 18,589.77 | |
| Trade payables, current | ||
| (A) Total outstanding dues of micro enterprises and small enterprises | 654.12 | |
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 10,873.87 | |
| Total Trade payable | 11,527.99 | |
| Other current financial liabilities | ||
| 1 | Lease Liabilities | 1,263.91 |
| 2 | Employee related liability | 349.48 |
| 3 | Other Payables | 0.58 |
| Total of other current financial liabilities | 1,613.97 | |
| Total current financial liabilities | 31,731.73 | |
| Other current liabilities | 122.11 | |
| 1 | Advances Received from Customers | 4.24 |
| 2 | Advance for sale of fixed assets | 13.50 |
| 3 | Statutory Dues Payable | 104.37 |
| Total of other current liabilities | 122.11 | |
| Provisions, current | 102.40 | |
| Current tax liabilities (Net) | 0.00 | |
| Deferred government grants, Current | 0.00 | |
| Total current liabilities | 31,956.24 | |
| 3 | Liabilities directly associated with assets in disposal group classified as held for sale | 1,292.00 |
| 4 | Regulatory deferral account credit balances and related deferred tax liability | 0.00 |
| Total liabilities | 39,021.49 | |
| Total equity and liabilites | 92,321.72 | |
| Disclosure of notes on assets and liabilities | ||
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-01-2026 | 01-04-2025 | |||||
| Date of end of reporting period | 31-03-2026 | 31-03-2026 | |||||
| Whether results are audited or unaudited | Audited | Audited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Items not to be reclassified to profit or loss in subsequent periods | 6.49 | 81.49 |
| Total Amount of items that will not be reclassified to profit and loss | 6.49 | 81.49 | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 1.63 | 20.51 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | 4.86 | 60.98 |
| Particulars | Year ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|
| A | Date of start of reporting period | 01-04-2025 | ||||
| B | Date of end of reporting period | 31-03-2026 | ||||
| C | Whether results are audited or unaudited | Audited | ||||
| D | Nature of report standalone or consolidated | Standalone | ||||
| Statement of cash flows | ||||||
| Cash flows from used in operating activities | ||||||
| Profit before tax | 2,892.30 | |||||
| Adjustments for reconcile profit (loss) | ||||||
| Adjustments for finance costs | 2,223.37 | |||||
| Adjustments for decrease (increase) in inventories | (5,412.19) | |||||
| Adjustments for decrease (increase) in trade receivables, current | 0.00 | |||||
| Adjustments for decrease (increase) in trade receivables, non-current | 2,133.45 | |||||
| Adjustments for decrease (increase) in other current assets | 0.00 | |||||
| Adjustments for decrease (increase) in other non-current assets | 0.00 | |||||
| Adjustments for other financial assets, non-current | (2,394.40) | |||||
| Adjustments for other financial assets, current | 0.00 | |||||
| Adjustments for other bank balances | (31.18) | |||||
| Adjustments for increase (decrease) in trade payables, current | 0.00 | |||||
| Adjustments for increase (decrease) in trade payables, non-current | 0.00 | |||||
| Adjustments for increase (decrease) in other current liabilities | 892.28 | |||||
| Adjustments for increase (decrease) in other non-current liabilities | 0.00 | |||||
| Adjustments for depreciation and amortisation expense | 2,754.84 | |||||
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | (15.39) | |||||
| Adjustments for provisions, current | 0.00 | |||||
| Adjustments for provisions, non-current | 0.00 | |||||
| Adjustments for other financial liabilities, current | 0.00 | |||||
| Adjustments for other financial liabilities, non-current | 0.00 | |||||
| Adjustments for unrealised foreign exchange losses gains | (651.41) | |||||
| Adjustments for dividend income | 0.00 | |||||
| Adjustments for interest income | 0.00 | |||||
| Adjustments for share-based payments | 0.00 | |||||
| Adjustments for fair value losses (gains) | 0.00 | |||||
| Adjustments for undistributed profits of associates | 0.00 | |||||
| Other adjustments for which cash effects are investing or financing cash flow | 0.00 | |||||
| Other adjustments to reconcile profit (loss) | (511.69) | |||||
| Other adjustments for non-cash items | 3,725.91 | |||||
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Total adjustments for reconcile profit (loss) | 2,713.59 | |||||
| Net cash flows from (used in) operations | 5,605.89 | |||||
| Dividends received | 0.00 | |||||
| Interest paid | 0.00 | |||||
| Interest received | 0.00 | |||||
| Income taxes paid (refund) | (202.24) | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) operating activities | 5,808.13 | |||||
| Cash flows from used in investing activities | ||||||
| Cash flows from losing control of subsidiaries or other businesses | 0.00 | |||||
| Cash flows used in obtaining control of subsidiaries or other businesses | 810.00 | |||||
| Other cash receipts from sales of equity or debt instruments of other entities | 0.00 | |||||
| Other cash payments to acquire equity or debt instruments of other entities | 0.00 | |||||
| Other cash receipts from sales of interests in joint ventures | 0.00 | |||||
| Other cash payments to acquire interests in joint ventures | 0.00 | |||||
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Proceeds from sales of property, plant and equipment | 289.46 | |||||
| Purchase of property, plant and equipment | 4,334.96 | |||||
| Proceeds from sales of investment property | 0.00 | |||||
| Purchase of investment property | 0.00 | |||||
| Proceeds from sales of intangible assets | 0.00 | |||||
| Purchase of intangible assets | 0.00 | |||||
| Proceeds from sales of intangible assets under development | 0.00 | |||||
| Purchase of intangible assets under development | 0.00 | |||||
| Proceeds from sales of goodwill | 0.00 | |||||
| Purchase of goodwill | 0.00 | |||||
| Proceeds from biological assets other than bearer plants | 0.00 | |||||
| Purchase of biological assets other than bearer plants | 0.00 | |||||
| Proceeds from government grants | 0.00 | |||||
| Proceeds from sales of other long-term assets | 0.00 | |||||
| Purchase of other long-term assets | 0.00 | |||||
| Cash advances and loans made to other parties | 0.00 | |||||
| Cash receipts from repayment of advances and loans made to other parties | 0.00 | |||||
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Dividends received | 0.00 | |||||
| Interest received | 31.18 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 46.37 | |||||
| Net cash flows from (used in) investing activities | (4,777.95) | |||||
| Cash flows from used in financing activities | ||||||
| Proceeds from changes in ownership interests in subsidiaries | 0.00 | |||||
| Payments from changes in ownership interests in subsidiaries | 0.00 | |||||
| Proceeds from issuing shares | 5,260.80 | |||||
| Proceeds from issuing other equity instruments | 0.00 | |||||
| Payments to acquire or redeem entity's shares | 0.00 | |||||
| Payments of other equity instruments | 0.00 | |||||
| Proceeds from exercise of stock options | 0.00 | |||||
| Proceeds from issuing debentures notes bonds etc | 0.00 | |||||
| Proceeds from borrowings | 96.15 | |||||
| Repayments of borrowings | 73.81 | |||||
| Payments of lease liabilities | 310.96 | |||||
| Dividends paid | 315.83 | |||||
| Interest paid | 2,116.97 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | (106.40) | |||||
| Net cash flows from (used in) financing activities | 2,432.98 | |||||
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 3,463.16 | |||||
| Effect of exchange rate changes on cash and cash equivalents | ||||||
| Effect of exchange rate changes on cash and cash equivalents | 0.00 | |||||
| Net increase (decrease) in cash and cash equivalents | 3,463.16 | |||||
| Cash and cash equivalents cash flow statement at beginning of period | 260.38 | |||||
| Cash and cash equivalents cash flow statement at end of period | 3,723.54 | |||||
| Whether results are audited or unaudited | Audited |
|---|---|
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Auditor's opinion | |
| Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results | Yes |
| Sr No. | Audit firm's name | Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI | Certificate valid upto | ||
| 1 | Walker Chandiok Co & LLP | Yes | 08-05-2026 | ||
|---|---|---|---|---|---|
| Mode of Fund Raising | Others |
|---|---|
| Description of mode of fund raising (Applicable in case of others is selected) | |
| Date of Raising Funds | 18-03-2026 |
| Amount Raised | 5,271.30 |
| Report filed for Quarter ended | 31-03-2026 |
| Monitoring Agency | Applicable |
| Monitoring Agency Name, if applicable | CARE Ratings Limited |
| Is there a Deviation / Variation in use of funds raised | No |
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders | |
| If Yes, Date of shareholder Approval | |
| Explanation for the Deviation / Variation | Not Applicable |
| Comments of the Audit Committee after review | No Comments |
| Comments of the auditors, if any | No Comments |
| Sr. | Original Object | Modified Object, if any | Original Allocation | Modified allocation, if any | Funds Utilised | Amount of Deviation/Variation for the quarter according to applicable object | Remarks if any |
| 1 | Repayment/ Prepayment of Secured/ Unsecured Loans from Bank/ NBFC in part or in full | Not Applicable | 150.00 | 150.00 | 150.00 | 0.00 | |
| 2 | Investment of Capital Expenditure | Not Applicable | 35.00 | 35.00 | 3.16 | 0.00 | |
| 3 | General Corporate Purpose | Not Applicable | 22.00 | 19.97 | 19.84 | 0.00 |
| Name of signatory | Mr. Rohan Parekh |
| Designation of person | Chief Financial Officer |
| Place | Thane |
| Date | 08-05-2026 |
Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) |
| Sr No. | Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. | ||||||||||||||||||||||||
| Details of the party (listed entity/subsidiary) entering into the transaction | Details of the counterparty | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit committee | Remarks on approval by audit committee | Value of the related party transaction ratified by the audit committee | Date of Audit Committee Meeting where the ratification was approved | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments | Details of the loans, inter-corporate deposits, advances or investments | Notes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | Opening balance | Closing balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.) | Details of other indebtedness | Cost | Tenure | Nature (loan/ advance/ intercorporate deposit/ investment ) | Interest Rate (%) | Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | ||||||||||
| 1 | Bajaj Healthcare Limited | Mr. Sajankumar Rameshwarlal Bajaj | Chairman & Managing Director | Remuneration | NA | 212.48 | 0.00 | 0.00 | |||||||||||||||||
| 2 | Bajaj Healthcare Limited | Mr. Anil Champalal Jain | Managing Director | Remuneration | NA | 174.98 | 0.00 | 0.00 | |||||||||||||||||
| 3 | Bajaj Healthcare Limited | Ms. Namrata Sajankumar Bajaj | Whole-Time Director | Remuneration | NA | 24.06 | 0.00 | 0.00 | |||||||||||||||||
| 4 | Bajaj Healthcare Limited | Mr. Pakshal Anil Jain | Whole-Time Director | Remuneration | NA | 24.15 | 0.00 | 0.00 | |||||||||||||||||
| 5 | Bajaj Healthcare Limited | Mrs. Harshavi Pakshal Jain | Wife of Mr. Pakshal Jain, Whole-Time Director & Daughter-in-law of Mr. Anil Jain, Managing Director | Remuneration | 20.00 | Approved by the Audit Committee | 9.56 | 0.00 | 0.00 | ||||||||||||||||
| 6 | Bajaj Healthcare Limited | Mrs. Khushi Jain | Daughter of Mr. Anil Champalal Jain, Managing Director & Sister of Mr. Pakshal Anil Jain, Whole-Time Director | Any other transaction | Legal & Professional Fees | 12.00 | Approved by the Audit Committee | 4.20 | 0.90 | 1.44 | |||||||||||||||
| 7 | Bajaj Healthcare Limited | Mrs. Nihita Bajaj Kumar | Daughter of Mr. Sajankumar Bajaj, Chairman & Managing Director & Sister of Ms. Namrata Bajaj, Whole-Time Director | Any other transaction | Legal & Professional Fees | 24.00 | Approved by the Audit Committee | 18.00 | 4.27 | 5.17 | |||||||||||||||
| 8 | Bajaj Healthcare Limited | Taradevi Rameshwarlal Bajaj Charitable Trust | Charitable Trust | Any other transaction | CSR Expenses | 100.00 | Approved by the Audit Committee | 0.00 | 0.00 | 0.33 | |||||||||||||||
| 9 | Bajaj Healthcare Limited | Genrx Pharmaceuticals Private Limited | Body corporate directly/ indirectly owned by or significantly influenced by Director/s or their relatives | Any other transaction | Operating Expenses incurred by Bajaj on behalf of Genrx Pharmaceuticals | 1,000.00 | Approved by the Audit Committee | 42.43 | 61.19 | 103.62 | Textual Information(1) | ||||||||||||||
| 10 | Bajaj Healthcare Limited | Bajaj Sindhudurg Rice Mills Limited | Body corporate directly/ indirectly owned by or significantly influenced by Director/s or their relatives | Any other transaction | Capital Advance | 20.00 | Approved by the Audit Committee | 10.00 | 17.46 | 18.52 | Advance | 0 | No Tenure | Unsecured | Corporate Business Purposes | ||||||||||
| Total value of transaction during the reporting period | 519.86 | ||||||||||||||||||||||||
| Textual Information(1) | The Company has acquired Genrx Pharmaceuticals Private Limited (in Liquidation) as a going concern through Sale Certificate dated 04.04.2025 & Possession Letter dated 05.04.2025. The status of Genrx Pharmaceuticals is in liquidation at ROC, hence there was no Board at the time of acquisition. Genrx Pharmaceuticals requires funding for their business/ operational purposes & to settle outstandings payments. On 03.06.2025, the Company filed an application before the National Company Law Tribunal (NCLT), Mumbai, seeking certain reliefs and concessions necessary for the effective takeover of the Genrx Pharmaceuticals Private Limited (in Liquidation), Corporate Debtor and to complete the acquisition as a going concern. |